CCHT(SZ:000661) Zhi Tong Cai Jing·2025-10-31 13:54Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of GenSci143 in patients with advanced solid tumors [1] Group 1: Product Development - GenSci143 is an innovative biopharmaceutical developed by Jinsai Pharmaceutical, intended for the treatment of various advanced solid tumors, including prostate cancer and lung cancer [1] - GenSci143 is a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA, which offers dual potential therapeutic effects of targeted chemotherapy and tumor immunotherapy [1] - The drug aims to overcome tumor heterogeneity and resistance caused by reduced expression of single targets, thereby covering a broader patient population and providing more durable anti-tumor efficacy [1]